Nasus Pharma Ltd (NSRX) income statement
NSRXNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 25, 2026Score 6/30
$2.70+0.09 (+3.45%)
Close on Nov 18, 2026Market cap $24.34MP/E –Yield –
Nasus Pharma Ltd income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- -0.4%
- Net margin
- -0.5%
- Return on equity, FY2025
- 2637.8%
Financial strength
- Current ratio
- 8.77
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 556.8%
Valuation
- P/E ratio
- –
- Price to sales
- 0.02
- Price to book
- 2.21
- Dividend yield
- –
See a number that looks wrong?